Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Feb;39(2):109–118. doi: 10.1111/j.1365-2125.1995.tb04416.x

Tolerance with beta 2-adrenoceptor agonists: time for reappraisal.

A Grove 1, B J Lipworth 1
PMCID: PMC1364946  PMID: 7742147

Abstract

1. In spite of the widespread use of beta 2-adrenoceptor agonists in the treatment of asthma controversy continues regarding their possible role in increasing asthma mortality and morbidity. There is however no evidence available to suggest that tolerance to the bronchodilator or anti-bronchoconstrictor effects of these drugs is responsible for the deleterious effects reported with the regular use of bronchodilators. 2. There is no conclusive evidence to suggest that tolerance develops to the bronchodilator effects of short-acting beta 2-adrenoceptor agonists. Tolerance does however appear to develop to the anti-bronchoconstrictor effects of these drugs. 3. With regard to the long-acting beta 2-adrenoceptor agonists, there is evidence to suggest that tolerance develops both to their anti-bronchoconstrictor, and bronchodilator effects. Tolerance was however demonstrated in the presence of improved symptom control, therefore the clinical relevance of this phenomenon is uncertain. 4. Systemic corticosteroids can modulate lymphocyte beta 2-adrenoceptor function both preventing, and reversing tolerance. The situation regarding the effects of systemic or inhaled corticosteroids on modulating bronchodilator responses in asthmatics is less clear. There is some evidence to suggest that inhaled corticosteroids are unable to prevent bronchodilator or systemic tolerance to long-acting beta 2-adrenoceptor agonists. 5. On the basis of the current evidence, the British Thoracic Society guidelines for the management of asthma appear appropriate with regard to their recommendations for the use of long-acting beta 2-adrenoceptor agonists.

Full text

PDF
109

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arvidsson P., Larsson S., Löfdahl C. G., Melander B., Wåhlander L., Svedmyr N. Formoterol, a new long-acting bronchodilator for inhalation. Eur Respir J. 1989 Apr;2(4):325–330. [PubMed] [Google Scholar]
  2. Barnes P. J., Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci. 1993 Dec;14(12):436–441. doi: 10.1016/0165-6147(93)90184-l. [DOI] [PubMed] [Google Scholar]
  3. Beach J. R., Young C. L., Harkawat R., Gardiner P. V., Avery A. J., Coward G. A., Walters E. H., Hendrick D. J. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm Pharmacol. 1993 Jun;6(2):155–157. doi: 10.1006/pulp.1993.1020. [DOI] [PubMed] [Google Scholar]
  4. Booth H., Fishwick K., Harkawat R., Devereux G., Hendrick D. J., Walters E. H. Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients. Thorax. 1993 Nov;48(11):1121–1124. doi: 10.1136/thx.48.11.1121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brodde O. E., Brinkmann M., Schemuth R., O'Hara N., Daul A. Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen. J Clin Invest. 1985 Sep;76(3):1096–1101. doi: 10.1172/JCI112063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brodde O. E., Howe U., Egerszegi S., Konietzko N., Michel M. C. Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators. Eur J Clin Pharmacol. 1988;34(2):145–150. doi: 10.1007/BF00614551. [DOI] [PubMed] [Google Scholar]
  7. Brodde O. E., Petrasch S., Bauch H. J., Daul A., Gnadt M., Oefler D., Michel M. C. Terbutaline-induced desensitization of beta 2-adrenoceptor in vivo function in humans: attenuation by ketotifen. J Cardiovasc Pharmacol. 1992 Sep;20(3):434–439. doi: 10.1097/00005344-199209000-00014. [DOI] [PubMed] [Google Scholar]
  8. Chapman K. R., Kesten S., Szalai J. P. Regular vs as-needed inhaled salbutamol in asthma control. Lancet. 1994 Jun 4;343(8910):1379–1382. doi: 10.1016/s0140-6736(94)92520-8. [DOI] [PubMed] [Google Scholar]
  9. Cheung D., Timmers M. C., Zwinderman A. H., Bel E. H., Dijkman J. H., Sterk P. J. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992 Oct 22;327(17):1198–1203. doi: 10.1056/NEJM199210223271703. [DOI] [PubMed] [Google Scholar]
  10. Cockcroft D. W., McParland C. P., Britto S. A., Swystun V. A., Rutherford B. C. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet. 1993 Oct 2;342(8875):833–837. doi: 10.1016/0140-6736(93)92695-p. [DOI] [PubMed] [Google Scholar]
  11. Davies A. O., Lefkowitz R. J. Regulation of beta-adrenergic receptors by steroid hormones. Annu Rev Physiol. 1984;46:119–130. doi: 10.1146/annurev.ph.46.030184.001003. [DOI] [PubMed] [Google Scholar]
  12. Derom E. Y., Pauwels R. A. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax. 1992 Jan;47(1):30–33. doi: 10.1136/thx.47.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ellul-Micallef R., Fenech F. F. Effect of intravenous prednisolone in asthmatics with diminished adrenergic responsiveness. Lancet. 1975 Dec 27;2(7948):1269–1271. doi: 10.1016/s0140-6736(75)90608-x. [DOI] [PubMed] [Google Scholar]
  14. Gibson G. J., Greenacre J. K., König P., Conolly M. E., Pride N. B. Use of exercise challenge to investigate possible tolerance to beta-adrenoceptor stimulation in asthma. Br J Dis Chest. 1978 Jul;72(3):199–206. doi: 10.1016/0007-0971(78)90042-6. [DOI] [PubMed] [Google Scholar]
  15. Godfrey S., Bar-Yishay E. Exercised-induced asthma revisited. Respir Med. 1993 Jul;87(5):331–344. doi: 10.1016/0954-6111(93)90046-3. [DOI] [PubMed] [Google Scholar]
  16. Grainger J., Woodman K., Pearce N., Crane J., Burgess C., Keane A., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax. 1991 Feb;46(2):105–111. doi: 10.1136/thx.46.2.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Greening A. P., Ind P. W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994 Jul 23;344(8917):219–224. doi: 10.1016/s0140-6736(94)92996-3. [DOI] [PubMed] [Google Scholar]
  18. Hauck R. W., Böhm M., Gengenbach S., Sunder-Plassmann L., Fruhmann G., Erdmann E. Beta 2-adrenoceptors in human lung and peripheral mononuclear leukocytes of untreated and terbutaline-treated patients. Chest. 1990 Aug;98(2):376–381. doi: 10.1378/chest.98.2.376. [DOI] [PubMed] [Google Scholar]
  19. Holgate S. T., Baldwin C. J., Tattersfield A. E. beta-adrenergic agonist resistance in normal human airways. Lancet. 1977 Aug 20;2(8034):375–377. doi: 10.1016/s0140-6736(77)90304-x. [DOI] [PubMed] [Google Scholar]
  20. Hui K. K., Conolly M. E., Tashkin D. P. Reversal of human lymphocyte beta-adrenoceptor desensitization by glucocorticoids. Clin Pharmacol Ther. 1982 Nov;32(5):566–571. doi: 10.1038/clpt.1982.204. [DOI] [PubMed] [Google Scholar]
  21. Juniper E. F., Frith P. A., Dunnett C., Cockcroft D. W., Hargreave F. E. Reproducibility and comparison of responses to inhaled histamine and methacholine. Thorax. 1978 Dec;33(6):705–710. doi: 10.1136/thx.33.6.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kerrebijn K. F., van Essen-Zandvliet E. E., Neijens H. J. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987 Apr;79(4):653–659. doi: 10.1016/s0091-6749(87)80163-x. [DOI] [PubMed] [Google Scholar]
  23. Kerstjens H. A., Brand P. L., Hughes M. D., Robinson N. J., Postma D. S., Sluiter H. J., Bleecker E. R., Dekhuijzen P. N., de Jong P. M., Mengelers H. J. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med. 1992 Nov 12;327(20):1413–1419. doi: 10.1056/NEJM199211123272003. [DOI] [PubMed] [Google Scholar]
  24. Kioumis I., Ukena D., Barnes P. J. Effect of nedocromil sodium on down-regulation of pulmonary beta-adrenoceptors. Clin Sci (Lond) 1989 Jun;76(6):599–602. doi: 10.1042/cs0760599. [DOI] [PubMed] [Google Scholar]
  25. Kraan J., Koëter G. H., vd Mark T. W., Sluiter H. J., de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol. 1985 Oct;76(4):628–636. doi: 10.1016/0091-6749(85)90786-9. [DOI] [PubMed] [Google Scholar]
  26. Larsson K., Martinsson A., Hjemdahl P. Influence of beta-adrenergic receptor function during terbutaline treatment on allergen sensitivity and bronchodilator response to terbutaline in asthmatic subjects. Chest. 1992 Apr;101(4):953–960. doi: 10.1378/chest.101.4.953. [DOI] [PubMed] [Google Scholar]
  27. Larsson S., Svedmyr N., Thiringer G. Lack of bronchial beta adrenoceptor resistance in asthmatics during long-term treatment with terbutaline. J Allergy Clin Immunol. 1977 Feb;59(2):93–100. doi: 10.1016/0091-6749(77)90209-3. [DOI] [PubMed] [Google Scholar]
  28. Lindén A., Bergendal A., Ullman A., Skoogh B. E., Löfdahl C. G. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax. 1993 May;48(5):547–553. doi: 10.1136/thx.48.5.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Lipworth B. J., Clark R. A., Dhillon D. P., Brown R. A., McDevitt D. G. Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. Br J Clin Pharmacol. 1988 Nov;26(5):527–533. doi: 10.1111/j.1365-2125.1988.tb05292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Lipworth B. J., Clark R. A., Dhillon D. P., McDevitt D. G. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1990 Aug;142(2):338–342. doi: 10.1164/ajrccm/142.2.338. [DOI] [PubMed] [Google Scholar]
  31. Lipworth B. J., Grove A., Jackson C. M. Asthma control. Lancet. 1994 Sep 10;344(8924):760–760. [PubMed] [Google Scholar]
  32. Lipworth B. J. Risks versus benefits of inhaled beta 2-agonists in the management of asthma. Drug Saf. 1992 Jan-Feb;7(1):54–70. doi: 10.2165/00002018-199207010-00007. [DOI] [PubMed] [Google Scholar]
  33. Lipworth B. J., Struthers A. D., McDevitt D. G. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis. 1989 Sep;140(3):586–592. doi: 10.1164/ajrccm/140.3.586. [DOI] [PubMed] [Google Scholar]
  34. Lipworth B. J. The beta-agonist controversy: fact or fiction? Clin Exp Allergy. 1992 Jul;22(7):659–664. doi: 10.1111/j.1365-2222.1992.tb00187.x. [DOI] [PubMed] [Google Scholar]
  35. Mitchell E. A. Is current treatment increasing asthma mortality and morbidity? Thorax. 1989 Feb;44(2):81–84. doi: 10.1136/thx.44.2.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Newnham D. M., Coutie W. J., McFarlane L. C., Lipworth B. J. Comparison of parameters of in vitro lymphocyte beta 2-adrenoceptor function in normal and asthmatic subjects. Eur J Clin Pharmacol. 1993;45(6):535–538. doi: 10.1007/BF00315310. [DOI] [PubMed] [Google Scholar]
  37. Newnham D. M., Ingram C. G., Earnshaw J., Palmer J. B., Dhillon D. P. Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respir Med. 1993 Aug;87(6):439–444. doi: 10.1016/0954-6111(93)90070-g. [DOI] [PubMed] [Google Scholar]
  38. Newnham D. M., McDevitt D. G., Lipworth B. J. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med. 1994 Jul;97(1):29–37. doi: 10.1016/0002-9343(94)90045-0. [DOI] [PubMed] [Google Scholar]
  39. Nijkamp F. P., Engels F., Henricks P. A., Van Oosterhout A. J. Mechanisms of beta-adrenergic receptor regulation in lungs and its implications for physiological responses. Physiol Rev. 1992 Apr;72(2):323–367. doi: 10.1152/physrev.1992.72.2.323. [DOI] [PubMed] [Google Scholar]
  40. O'Connor B. J., Aikman S. L., Barnes P. J. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med. 1992 Oct 22;327(17):1204–1208. doi: 10.1056/NEJM199210223271704. [DOI] [PubMed] [Google Scholar]
  41. Paggiaro P. L., Dente F. L., Vagaggini B., Bacci E., Talini D., Testi R., Mapp C. E., Fabbri L. M., Giuntini C. Salbutamol plus beclomethasone dipropionate, but not salbutamol alone, completely prevent early and late asthmatic responses to allergen. Respir Med. 1991 Sep;85(5):401–406. doi: 10.1016/s0954-6111(06)80185-x. [DOI] [PubMed] [Google Scholar]
  42. Pearce N., Grainger J., Atkinson M., Crane J., Burgess C., Culling C., Windom H., Beasley R. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax. 1990 Mar;45(3):170–175. doi: 10.1136/thx.45.3.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Pearlman D. S., Chervinsky P., LaForce C., Seltzer J. M., Southern D. L., Kemp J. P., Dockhorn R. J., Grossman J., Liddle R. F., Yancey S. W. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992 Nov 12;327(20):1420–1425. doi: 10.1056/NEJM199211123272004. [DOI] [PubMed] [Google Scholar]
  44. Ramage L., Lipworth B. J., Ingram C. G., Cree I. A., Dhillon D. P. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 1994 May;88(5):363–368. doi: 10.1016/0954-6111(94)90042-6. [DOI] [PubMed] [Google Scholar]
  45. Ramsdale E. H., Otis J., Kline P. A., Gontovnick L. S., Hargreave F. E., O'Byrne P. M. Prolonged protection against methacholine-induced bronchoconstriction by the inhaled beta 2-agonist formoterol. Am Rev Respir Dis. 1991 May;143(5 Pt 1):998–1001. doi: 10.1164/ajrccm/143.5_Pt_1.998. [DOI] [PubMed] [Google Scholar]
  46. Repsher L. H., Anderson J. A., Bush R. K., Falliers C. J., Kass I., Kemp J. P., Reed C., Siegel S., Webb D. R. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest. 1984 Jan;85(1):34–38. doi: 10.1378/chest.85.1.34. [DOI] [PubMed] [Google Scholar]
  47. Repsher L. H., Miller T. D., Smith S. The lack of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Ann Allergy. 1981 Nov;47(5 Pt 2):405–409. [PubMed] [Google Scholar]
  48. Sears M. R., Taylor D. R., Print C. G., Lake D. C., Li Q. Q., Flannery E. M., Yates D. M., Lucas M. K., Herbison G. P. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. doi: 10.1016/0140-6736(90)93098-a. [DOI] [PubMed] [Google Scholar]
  49. Spitzer W. O., Suissa S., Ernst P., Horwitz R. I., Habbick B., Cockcroft D., Boivin J. F., McNutt M., Buist A. S., Rebuck A. S. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992 Feb 20;326(8):501–506. doi: 10.1056/NEJM199202203260801. [DOI] [PubMed] [Google Scholar]
  50. Tashkin D. P., Conolly M. E., Deutsch R. I., Hui K. K., Littner M., Scarpace P., Abrass I. Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects. Am Rev Respir Dis. 1982 Feb;125(2):185–193. doi: 10.1164/arrd.1982.125.2.185. [DOI] [PubMed] [Google Scholar]
  51. Taylor D. R., Sears M. R. Regular beta-adrenergic agonists. Evidence, not reassurance, is what is needed. Chest. 1994 Aug;106(2):552–559. doi: 10.1378/chest.106.2.552. [DOI] [PubMed] [Google Scholar]
  52. Teale C., Pearson S. B. Regular nebulised terbutaline in chronic obstructive airways disease: dose-response studies fail to detect tolerance. Br J Clin Pharmacol. 1991 Jul;32(1):111–114. doi: 10.1111/j.1365-2125.1991.tb05621.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Twentyman O. P., Finnerty J. P., Harris A., Palmer J., Holgate S. T. Protection against allergen-induced asthma by salmeterol. Lancet. 1990 Dec 1;336(8727):1338–1342. doi: 10.1016/0140-6736(90)92894-n. [DOI] [PubMed] [Google Scholar]
  54. Ullman A., Hedner J., Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis. 1990 Sep;142(3):571–575. doi: 10.1164/ajrccm/142.3.571. [DOI] [PubMed] [Google Scholar]
  55. Ullman A., Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax. 1988 Sep;43(9):674–678. doi: 10.1136/thx.43.9.674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Vathenen A. S., Knox A. J., Higgins B. G., Britton J. R., Tattersfield A. E. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet. 1988 Mar 12;1(8585):554–558. doi: 10.1016/s0140-6736(88)91352-9. [DOI] [PubMed] [Google Scholar]
  57. Waalkens H. J., Gerritsen J., Koëter G. H., Krouwels F. H., van Aalderen W. M., Knol K. Budesonide and terbutaline or terbutaline alone in children with mild asthma: effects on bronchial hyperresponsiveness and diurnal variation in peak flow. Thorax. 1991 Jul;46(7):499–503. doi: 10.1136/thx.46.7.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Weber R. W., Smith J. A., Nelson H. S. Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration. J Allergy Clin Immunol. 1982 Dec;70(6):417–422. doi: 10.1016/0091-6749(82)90003-3. [DOI] [PubMed] [Google Scholar]
  59. van Schayck C. P., Dompeling E., van Herwaarden C. L., Folgering H., Verbeek A. L., van der Hoogen H. J., van Weel C. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ. 1991 Dec 7;303(6815):1426–1431. doi: 10.1136/bmj.303.6815.1426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. van Schayck C. P., Graafsma S. J., Visch M. B., Dompeling E., van Weel C., van Herwaarden C. L. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol. 1990 Nov;86(5):793–800. doi: 10.1016/s0091-6749(05)80185-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES